iM4TB, through its participation in ERA4TB – a European Union’s Horizon 2020 research and innovation program – is supporting initial development of a long-acting injectable (LAI) version of Macozinone, a potential new therapy for tuberculosis (TB).

LAI Macozinone could help address some of the biggest challenges in TB treatment: facilitating access, improving patient adherence even after symptoms subside, and lowering the risk of drug resistance.

Read more in Medincell’s press release.